Description
The Department of Veterans Affairs, Networking Contracting Office, intends to enter into a sole source procurement with Novartis Pharmaceuticals Corporation for Lu-177 vipivotide tetraxetan (PLUVICTO), a radioligand therapeutic agent for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive and metastatic castration-resistant prostate cancer. The contractor will provide radiopharmaceutical preparation and delivery of Lu-177 vipivotide tetraxetan doses to the Nuclear Medicine Service at VA Connecticut Healthcare. Deliveries will be made Monday through Friday between 7:00 am and 3:00 pm. The contractor must be licensed by the Nuclear Regulatory Commission and regularly established in the business of providing radiopharmaceuticals.
• The contract will have a Period of Performance from September 1, 2026, to August 31, 2027.
• A total of 74 doses of Pluvicto will be required to treat prostate-specific membrane antigen (PSMA)-Positive patients.
• The contractor's employees will deliver to the PET/CT Service and give deliveries directly to the PET Technologist on duty.
• The contractor will provide for the placement of one or more telephone delivery orders per day for items listed in the Pricing and Cost Schedule.